Oramed Pharmaceuticals Inc. — Director's Dealing 2026

Jan 5, 2026

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ORAMED PHARMACEUTICALS INC. (ORMP)
CIK: 0001176309
Period of Report: 2025-12-31

Reporting Person: Mayer Arie (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-12-31	Common Stock	A	30000	—	Acquired	163109	Direct
2025-12-31	Common Stock	A	4900	—	Acquired	168009	Direct

Footnotes

F1: Represents Restricted Stock Units ("RSUs"). The RSUs will vest ratably in three annual tranches beginning January 1, 2027. Each RSU represents the right to receive one share of common stock, par value $0.012 per share ("Common Stock"), of the Issuer.

F2: Represents RSUs. The RSUs will vest in quarterly installments over a one-year period starting April 1, 2026. Each RSU represents the right to receive one share of Common Stock of the Issuer.